History
Documents created during the development process.
Review proposal consultation
Other information
-
TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: guidance (MS Word format)
-
Background information
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 62 KB)
-
-
-
Appendix A: Decision paper considered by the Institute's Guidance Executive
-
Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 39 KB)
Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: final appraisal determination
-
-
Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: final appraisal determination
-
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: appraisal consultation document
Evaluation Report
-
Glioma overview
-
2006/060 NICE appraisal on carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Appeal announcement
Methods for reanalyses of cost-effectiveness of TMZ based on subgroup
-
Methods for reanalyses of cost-effectiveness of TMZ based on subgroup
-
Methods for reanalyses of cost-effectiveness of TMZ based on subgroup (PDF 70 KB)
Final Appraisal Determination: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Response to consultee and commentator comments on the ACD
-
Response to consultee and commentator comments on the ACD
-
Response to consultee and commentator comments on the ACD (PDF 348 KB)
Consultee and commentator comments on the ACD
-
Consultee and commentator comments on the ACD
-
Association of British Neurologists
-
-
Brain and Spine Foundation
-
-
Brain Tumour UK
-
-
Cancer Research UK
-
-
CancerBACUP
-
-
Department of Health
-
-
Institute of Cancer Research
-
-
Link Pharmaceuticals Ltd
-
-
National Hospital for Neurology & Neurosurgery
-
-
NHS Quality Improvement Scotland
-
-
Royal College of Radiologists (RCR), the Joint Collegiate Council on Clinical Oncology (JCCCO) and the Royal College of Physicians (RCP) (Joint Comments)
-
-
Samantha Dickson Research Trust
-
-
Schering-Plough Ltd
-
-
Society of British Neurological Surgeons
-
-
Welsh Assembly Government
-
Response to public and web comments on the ACD
-
Response to public and web comments on the ACD
-
Expert comments on the ACD
-
Expert comments on the ACD
-
Redman
-
-
Mitchell
-
-
Brada
-
Additional analyses
-
Additional analyses
-
Re-analysis/sensitivity analysis with different treatment on disease progression between TMZ with RT and RT only arm
-
-
Re-analysis based on Link comments on ACD Appendix 2
-
Re-analysis based on Link comments on ACD Appendix 2 (PDF 28 KB)
Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (appraisal consultation)
Overview
-
Overview
-
Assessment report: Glioma (newly diagnosed and high grade) - carmustine implants and gemozolomide
-
Assessment report: Glioma (newly diagnosed and high grade) - carmustine implants and gemozolomide
-
Consultee and commentator comments on the assessment report
-
Consultee and commentator comments on the assessment report
-
Association of British Neurologists
-
-
Brain & Central Nervous System Tumours Guideline Development Group
-
Brain & Central Nervous System Tumours Guideline Development Group (PDF 33 KB)
-
British National Formulary
-
-
British Oncology Pharmacy Association
-
-
CancerBACUP
-
-
Link Pharmaceuticals Ltd
-
-
NHS Quality Improvement Scotland
-
-
Royal College of Nursing
-
-
Society of British Neurological Surgeons (SBNS)
-
-
Schering-Plough Ltd
-
Response to consultee and commentator comments on the commercial-in-confidence stripped assessment report
-
Response to consultee and commentator comments on the commercial-in-confidence stripped assessment report
-
Additional analysis submitted by assessment group in response to consultee and commentator comments
-
Additional analysis submitted by assessment group in response to consultee and commentator comments
-
Non-manufacturer submissions
-
Non-manufacturer submissions
-
Brain and Spine Foundation
-
-
CancerBACUP
-
-
Royal College of Nursing
-
-
Tenovus Cancer Information Centre
-
Manufacturer submissions (executive summary only)
-
Manufacturer submissions (executive summary only)
-
Link Pharmaceuticals Ltd
-
-
Schering-Plough Ltd
-
Expert written personal statements
-
Expert written personal statements
-
Brada
-
-
Cruickshank
-
-
Rees
-
-
Walker
-
-
Mitchell
-
Final scope
-
Final scope
-
Summary of comments from consultees and commentators on the draft scope
-
Summary of comments from consultees and commentators on the draft scope
-
Summary of comments from consultees and commentators on the draft scope (PDF 41 KB)
Response to comments on the provisional matrix of consultees and commentators
-
Response to comments on the provisional matrix of consultees and commentators
-
Response to comments on the provisional matrix of consultees and commentators (PDF 21 KB)
Archive: Provisional matrix of consultees and commentators
-
Archive: Provisional matrix of consultees and commentators
-
Archive: Provisional matrix of consultees and commentators (PDF 29 KB)